BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 34020723)

  • 1. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
    Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
    Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N
    Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
    Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
    Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
    Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
    Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
    AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent oligodendroglioma with changed 1p/19q status.
    Barresi V; Mafficini A; Calicchia M; Piredda ML; Musumeci A; Ghimenton C; Scarpa A
    Neuropathology; 2022 Apr; 42(2):160-166. PubMed ID: 35144313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors.
    Kitahama K; Iijima S; Sumiishi A; Hayashi A; Nagahama K; Saito K; Sasaki N; Kobayashi K; Shimizu S; Nagane M; Shibahara J
    Brain Tumor Pathol; 2021 Jan; 38(1):23-29. PubMed ID: 32989606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
    Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
    J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
    Sathornsumetee S; Cheunsuchon P; Sangruchi T
    World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.
    Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH
    Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by¬†FISH.
    de Biase D; Acquaviva G; Visani M; Marucci G; De Leo A; Maloberti T; Sanza V; Di Oto E; Franceschi E; Mura A; Ragazzi M; Serra S; Froio E; Bisagni A; Brandes AA; Pession A; Tallini G
    J Mol Diagn; 2021 Sep; 23(9):1185-1194. PubMed ID: 34186176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.